Sugi Predict

Sugi Predict / Compounds / SCHEMBL21997783

SCHEMBL21997783

SCHEMBL21997783

CCOC(=O)COC1C[C@@H](C)N(C(=O)O)[C@@H](C)C1

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 1/20 0.37
▸ MGAM O43451 1/20 0.34
▸ GAA P10253 1/20 0.34
▸ SI P14410 1/20 0.34
▸ MGAM2 Q2M2H8 1/20 0.34
▸ ITGB3 P05106 4/20 0.34
▸ ITGA2B P08514 4/20 0.34
▸ HRH3 Q9Y5N1 1/20 0.34
▸ TSHR P16473 1/20 0.33
▸ ALDH1A1 P00352 3/20 0.32
▸ TRPA1 O75762 1/20 0.32
▸ HSD11B1 P28845 1/20 0.32
▸ KDM4E B2RXH2 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ ALOX15 P16050 1/20 0.31
▸ MAPT P10636 1/20 0.30
▸ CHRM1 P11229 1/20 0.30
▸ EPHX2 P34913 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22032233 0.83 KMT2A (0.39) KMT2AMGAMGAASIMGAM2
SCHEMBL23086693 0.83 KMT2A (0.39) KMT2AMGAMGAASIMGAM2
SCHEMBL23086683 0.83 KMT2A (0.39) KMT2AMGAMGAASIMGAM2
SCHEMBL23086685 0.83 KMT2A (0.39) KMT2AMGAMGAASIMGAM2
SCHEMBL23807838 0.81 CHRM2 (0.39) KMT2AITGB3ITGA2BTSHRALDH1A1
SCHEMBL29170244 0.78 MGAM (0.36) KMT2AMGAMGAASIMGAM2
SCHEMBL29170241 0.78 MGAM (0.36) KMT2AMGAMGAASIMGAM2
SCHEMBL27098386 0.76 GAA (0.41) KMT2AMGAMGAASIMGAM2
SCHEMBL20120713 0.76 KMT2A (0.40) KMT2AMGAMGAASIMGAM2
SCHEMBL26352273 0.75 GAA (0.40) KMT2AMGAMGAASIMGAM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239777-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-07-18 — — US disclosed
US-11807636-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-11-07 — — US disclosed
US-11352350-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2022-06-07 — — US disclosed
US-20210323952-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2021-10-21 — — US disclosed
EP-3886904-A1 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2021-10-06 — — EP disclosed
US-11117889-B1 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2021-09-14 — — US disclosed
WO-2020113233-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2020-06-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11117889-B1 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 KMT2A 445/4885MGAM 738/4885GAA 1234/4885
US-11352350-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 KMT2A 445/4885MGAM 738/4885GAA 1234/4885
US-20210323952-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 KMT2A 445/4885MGAM 738/4885GAA 1234/4885
US-20240239777-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 KMT2A 445/4885MGAM 738/4885GAA 1234/4885
US-11807636-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 KMT2A 445/4885MGAM 738/4885GAA 1234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.